id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-351567-ifoe8x28	Rabi, Firas A.	SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far	2020-03-20		.txt	text/plain	5766	241	49	Initial virological and clinical findings Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Controlled Trial of Ebola Virus Disease Therapeutics Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro First Case of 2019 Novel Coronavirus in the United States NIH Clinical Trial of Remdesivir to Treat COVID-19 Begins Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Protease inhibitors targeting coronavirus and filovirus entry Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities TACTIC Investigative Team a phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: Study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC) However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic.	cache/cord-351567-ifoe8x28.txt	txt/cord-351567-ifoe8x28.txt
